<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284804</url>
  </required_header>
  <id_info>
    <org_study_id>MDX060-05/05E</org_study_id>
    <nct_id>NCT00284804</nct_id>
  </id_info>
  <brief_title>A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease</brief_title>
  <official_title>An Open-label, Randomized, Multicenter, Phase II Study of MDX-060 in Combination With Gemcitabine, MDX060 in Combination With Dexamethasone, and Gemcitabine Monotherapy in Patients With Relapsed or Refractory Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the objective response rate in patients with relapsed or
      refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or
      gemcitabine alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives include:

        -  to characterize progression-free survival

        -  to characterize time to progression

        -  to determine response duration

        -  to characterize the effect of study drug on health-related quality of life

        -  to explore the correlation of positron emission tomography (PET) scan results with
           objective responses observed with conventional imaging in this patient population

        -  to characterize the immunogenicity response of MDX-060

        -  to characterize the safety of MDX-060, and

        -  to characterize the pharmacokinetic profile of MDX-060
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Day 50/57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Day 50/57</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>MDX-060 plus standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDX-060 in combination with gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDX-060</intervention_name>
    <description>anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg</description>
    <arm_group_label>MDX-060 plus standard of care</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>anti-CD30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Hodgkin's disease [HD] (excluding HIV-associated HD)

          -  Patients must have read, understood, and provided written informed consent and Health
             Insurance Portability and Accountability Act (HIPAA) authorization after the nature of
             the study has been fully explained

          -  Patients must have failed or relapsed following second line (i.e., salvage)
             chemotherapy or relapsed or failed following autologous stem cell transplant

          -  ECOG Performance Status of 0-2

          -  Patients must have bi-measurable disease

          -  At least 4 weeks since the last chemotherapy or radiation therapy with clinical
             evidence of recovery from any toxicity associated with such treatment

          -  Life expectancy 12 weeks or greater

          -  Screening laboratory values must be met

          -  Patients on corticosteroids must be tapered off the medication 2 weeks prior to study
             drug administration and remain off corticosteroids until study completion.

        Exclusion Criteria:

          -  Previous treatment with any anti-CD30 antibody

          -  History of allogeneic transplant

          -  Any tumor lesion 10cm or greater in diameter

          -  Any other malignancy, excluding basal or squamous cell carcinoma of the skin, or
             cervical carcinoma in situ. Any cancer from which the patient has been disease free
             for at least 5 years is permissible.

          -  Any significant active or chronic infection

          -  Apparent active or latent tuberculosis (TB) infection

          -  Patients who are pregnant or nursing

          -  Any underlying medical condition which, in the investigator's opinion, will make the
             administration of the study drug hazardous or obscure the interpretation of adverse
             events

          -  Concomitant chemotherapy, steroids, investigational agents, other anti-HD biologics,
             or radiation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medarex Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Medarex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope, National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Oncology of the Central Valley</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego/Moores UCSD Cancer Center</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Cancer Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital Center</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology/Oncology, Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute, PLLC</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center, The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506-9162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2006</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2010</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed or refractory Hodgkin's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

